11,646 reports of this reaction
2.1% of all LENALIDOMIDE reports
#9 most reported adverse reaction
WHITE BLOOD CELL COUNT DECREASED is the #9 most commonly reported adverse reaction for LENALIDOMIDE, manufactured by Celgene Corporation. There are 11,646 FDA adverse event reports linking LENALIDOMIDE to WHITE BLOOD CELL COUNT DECREASED. This represents approximately 2.1% of all 557,894 adverse event reports for this drug.
Patients taking LENALIDOMIDE who experience white blood cell count decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WHITE BLOOD CELL COUNT DECREASED is a less commonly reported adverse event for LENALIDOMIDE, but still significant enough to appear in the safety profile.
In addition to white blood cell count decreased, the following adverse reactions have been reported for LENALIDOMIDE:
The following drugs have also been linked to white blood cell count decreased in FDA adverse event reports:
WHITE BLOOD CELL COUNT DECREASED has been reported as an adverse event in 11,646 FDA reports for LENALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WHITE BLOOD CELL COUNT DECREASED accounts for approximately 2.1% of all adverse event reports for LENALIDOMIDE, making it a notable side effect.
If you experience white blood cell count decreased while taking LENALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.